RayzeBio, Inc. Common Stock Aktie - Unternehmensdaten & Kurse - US75525N1072 | goSPATZ

RayzeBio, Inc. Common Stock

Acción · US75525N1072 · RYZB (XNAS)

Resumen Indicadores financieros

Sin cotización

n/a

Performance

Day	Week	Month	3 Months	6 Months	1 Year	5 Years
-	-	-	-	0,00 %	0,00 %	160,38 %

Company Profile for RayzeBio, Inc. Common Stock Share

RayzeBio, Inc. develops radiopharmaceutical therapeutics (RPT) for the treatment of cancer. The company’s lead drug candidate is RYZ101, which is in phase 3 clinical trial for the treatment of gasteroenteropancreatic neuroendocrine tumors (GEP-NETs). It also develops RYZ801, a novel proprietary peptide that targets GPC3 for delivery of Ac225 for the treatment of hepatocellular carcinoma (HCC); RYZ811, a paired diagnostic imaging agent with the peptide binder, chelator, and Ga68 as the radioisotope; and a novel proprietary small molecule that targets CA9 for delivery of Ac225 for the treatment of ccRCC. The company was incorporated in 2020 and is based in San Diego, California.

Company Data

Name RayzeBio, Inc. Common Stock

Company RayzeBio, Inc. Common Stock

Symbol RYZB

Primary Exchange

NASDAQ

ISIN US75525N1072

Asset Class Share

Sector Healthcare

Industry Biotechnology

CEO Dr. Kenneth Song M.D.

Market Capitalization 4 Mrd.

Country United States of America

Currency USD

Employees 0,1 T

IPO Date 2023-09-15

Ticker Symbols

Name	Symbol
NASDAQ	RYZB

More Shares

Investors who RayzeBio, Inc. Common Stock hold also have the following shares in their portfolio:

MUL-LYX. JPX-NI.400 DEODH ETF

The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.

Imprint Data Protection Blog Community Feedback Changelog

Im App Store herunterladen

Bei Google Play herunterladen

All rights reserved © LCP GmbH 2025